ARVN Insider Trading
Insider Ownership Percentage: 5.23%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $769,402.28
Arvinas Share Price & Price History
Current Price: $9.21
Price Change: ▲ Price Increase of +0.16 (1.77%)
As of 04/28/2025 05:00 PM ET
Arvinas Insider Trading History
Arvinas Institutional Trading History
Data available starting January 2016
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Read More on Arvinas
Volume
1,292,522 shs
Average Volume
1,142,039 shs
Market Capitalization
$633.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.3
Who are the company insiders with the largest holdings of Arvinas?
Who are the major institutional investors of Arvinas?
Arvinas' top institutional shareholders include:
- Rhumbline Advisers — 0.13%
- Assenagon Asset Management S.A. — 0.12%
- Hennion & Walsh Asset Management Inc. — 0.09%
- IMC Chicago LLC — 0.00%
- Exchange Traded Concepts LLC — 0.02%
- Teacher Retirement System of Texas — 0.02%
Learn More about top institutional investors of Arvinas stock.
Which major investors are selling Arvinas stock?
Within the last quarter, ARVN stock was sold by these institutional investors:
- Assenagon Asset Management S.A.
- Hennion & Walsh Asset Management Inc.
- Teacher Retirement System of Texas
Within the last year, company insiders that have sold Arvinas company stock include:
- John G Houston (CEO)
- Sean A Cassidy (CFO)
- Ian Taylor (Insider)
- Noah Berkowitz (Insider)
Learn More investors selling Arvinas stock.
Which major investors are buying Arvinas stock?
Within the last quarter, ARVN stock was acquired by institutional investors including:
- IMC Chicago LLC
- Allspring Global Investments Holdings LLC
- Exchange Traded Concepts LLC
- GAMMA Investing LLC
- Rhumbline Advisers